35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin

Nakhia Impex

Status: Enrolling

Conditions: Skin Inflammation; Cosmetic Skin

Treatments: Drug: 35 kDa hyaluronan fragment HA35 injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT06387212

HUI0001

Details and patient eligibility

About

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Skin problems include but are not limited to dry skin, dark skin, and coarse pores.
• Chronic skin inflammation, pigmentation, erythema, etc.
• Cooperate with the experimental requirements and be able to complete the score independently。

Exclusion criteria

• Pregnant or lactating women.
• Suffering from psychological or mental illness.
• Life is not regular, overeating.
• Hypersensitive to hyaluronic acid, and has a scar constitution.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

DermaShine PRO negative microneedles instrument

Experimental group

Treatment:

Drug: 35 kDa hyaluronan fragment HA35 injection